HanchorBio Inc., a leading biotechnology firm headquartered in Taiwan (TW), has been at the forefront of innovative solutions since its establishment. Specialising in advanced biopharmaceuticals and cutting-edge research, the company operates primarily in the Asia-Pacific region, with a growing presence in global markets. Founded in 2015, HanchorBio has achieved significant milestones, including the development of unique therapeutic products that address unmet medical needs. Their core offerings, which include monoclonal antibodies and biologics, are distinguished by their precision and efficacy, setting new standards in the industry. With a strong commitment to research and development, HanchorBio has positioned itself as a key player in the biopharmaceutical landscape, recognised for its contributions to healthcare advancements and patient outcomes.
How does HanchorBio Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
HanchorBio Inc.'s score of 20 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
HanchorBio Inc., headquartered in Taiwan (TW), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As a result, HanchorBio Inc. has not established any significant climate commitments or initiatives to reduce its carbon footprint. The lack of emissions data and reduction strategies suggests that the company may still be in the early stages of developing its climate action framework. In the context of the industry, it is essential for companies to adopt robust climate commitments and transparent reporting practices to align with global sustainability goals. HanchorBio Inc. may benefit from exploring industry-standard initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP) to enhance its climate strategy in the future.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
HanchorBio Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
